Antibody–drug conjugate (ADC) is typically composed of a monoclonal antibody (mAbs)
covalently attached to a cytotoxic drug via a chemical linker. It combines both the …

Nine different antibody–drug conjugates (ADCs) are currently approved as cancer
treatments, with dozens more in preclinical and clinical development. The primary goal of …

The large number of emerging antibody-drug conjugates (ADCs) for cancer therapy has
resulted in a significant market 'boom', garnering worldwide attention. Despite ADCs …

Antibody–drug conjugates (ADCs) harness the highly specific targeting capabilities of an
antibody to deliver a cytotoxic payload to specific cell types. They have garnered …

Antibody–drug conjugates (ADCs) are novel drugs that exploit the specificity of a
monoclonal antibody (mAb) to reach target antigens expressed on cancer cells for the …

Antibody–drug conjugates (ADCs) are immunoconjugates comprised of a monoclonal
antibody tethered to a cytotoxic drug (known as the payload) via a chemical linker. The ADC …

Antibody-drug conjugates (ADCs) and immunotherapy have prompted a revolution in the
treatment of cancer. However, only a limited fraction of patients obtained a long-term benefit; …

Antibody-drug conjugates (ADCs) are complex engineered therapeutics consisting of
monoclonal antibodies, directed toward tumor-associated antigens, to which highly potent …

Antibody–drug conjugates (ADCs) are a family of targeted therapeutic agents for the
treatment of cancer. ADC development is a rapidly expanding field of research, with over 80 …

The primary purpose of ADCs is to increase the efficacy of anticancer medications by
minimizing systemic drug distribution and targeting specific cells. Antibody conjugates …